These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33512849)

  • 1. Acute HIV at the Time of Initiation of Pre-exposure or Post-exposure Prophylaxis: Impact on Drug Resistance and Clinical Outcomes.
    Johnson KA; Chen MJ; Kohn R; Sachdev D; Bacon O; Lee S; Cohen SE
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):818-825. PubMed ID: 33512849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022.
    Misra K; Huang JS; Udeagu CN; Forgione L; Xia Q; Torian LV
    Clin Infect Dis; 2024 May; 78(5):1240-1245. PubMed ID: 37976185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.
    Elliott T; Sanders EJ; Doherty M; Ndung'u T; Cohen M; Patel P; Cairns G; Rutstein SE; Ananworanich J; Brown C; Fidler S
    J Int AIDS Soc; 2019 Dec; 22(12):e25419. PubMed ID: 31850686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019.
    Harvala H; Reynolds C; Ijaz S; Maddox V; Penchala SD; Amara A; Else L; Brailsford S; Khoo S
    Sex Transm Infect; 2022 Mar; 98(2):132-135. PubMed ID: 33782147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
    Naicker CL; Mansoor LE; Dawood H; Naidoo K; Singo D; Matten D; Williamson C; Abdool Karim Q
    BMC Infect Dis; 2020 Jul; 20(1):532. PubMed ID: 32698772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study.
    Shan D; Xue H; Yu F; Zan X; Liu H; Liu J; Han M; Zhang D
    J Med Internet Res; 2023 May; 25():e42729. PubMed ID: 37204828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Disengagement in Care for Individuals Receiving Pre-exposure Prophylaxis (PrEP).
    Zucker J; Carnevale C; Richards P; Slowikowski J; Borsa A; Gottlieb F; Vakkur I; Hyden C; Olender S; Cohall A; Gordon P; Sobieszczyk ME
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):e104-e108. PubMed ID: 30985557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.
    Furukawa NW; Smith DK; Gonzalez CJ; Huang YA; Hanna DB; Felsen UR; Zhu W; Arnsten JH; Patel VV
    Public Health Rep; 2020; 135(2):202-210. PubMed ID: 32027559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are current guidelines adapted for patient eligibility to PrEP? A case report.
    Van Obberghen EK; Viard D; Lafeuillade A; Civiletti A; Rocher F; Drici MD
    BMC Infect Dis; 2019 Jul; 19(1):601. PubMed ID: 31291899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary HIV-1 infection in users of pre-exposure prophylaxis.
    Ambrosioni J; Petit E; Liegeon G; Laguno M; Miró JM
    Lancet HIV; 2021 Mar; 8(3):e166-e174. PubMed ID: 33316212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HIV drug resistance prevalence among recently diagnosed HIV-positive men who have sex with men in a setting of high PrEP use.
    King JM; Giallonardo FD; Shaik A; McGregor S; Yeung JYK; Sivaruban T; Lee FJ; Cunningham P; Dwyer DE; Nigro SJ; Grulich AE; Kelleher AD
    J Int AIDS Soc; 2024 Jul; 27(7):e26308. PubMed ID: 39034597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Resistance During HIV Pre-Exposure Prophylaxis.
    Gibas KM; van den Berg P; Powell VE; Krakower DS
    Drugs; 2019 Apr; 79(6):609-619. PubMed ID: 30963509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
    Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
    AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
    van de Vijver DA; Nichols BE; Abbas UL; Boucher CA; Cambiano V; Eaton JW; Glaubius R; Lythgoe K; Mellors J; Phillips A; Sigaloff KC; Hallett TB
    AIDS; 2013 Nov; 27(18):2943-51. PubMed ID: 23939237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate PrEP when accessing PEP: A service evaluation.
    Cockbain B; Whitlock G;
    HIV Med; 2022 Nov; 23(10):1108-1112. PubMed ID: 35352455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study.
    Peng Q; Liu X; Tang X; Zhang Q; Zhao J; Zheng C; Zhao F; Zhou Y; Zhang L; Sun L; Zhang H; Jia X; Song Y; Cao T; Wang S; Rao M; Chen Z; Wang H; He Y
    Chin Med J (Engl); 2022 Nov; 135(22):2730-2737. PubMed ID: 36719360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.